Ruxolitinib cream has shown promising long-term safety and efficacy for the treatment of atopic dermatitis (AD), based on results from two large-scale phase 3 clinical trials—TRuE-AD1 and TRuE-AD2—published in The Journal of the American Academy of Dermatology. These studies involved more than 1,000 patients aged 12 and older who were monitored over a 52-week period. […]
September9, 2022- Today, the U.S. Food and Drug Administration approved SOTYKTU (Deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. “Based on its ability to improve skin clarity shown in the POETYK PSO clinical trials, Sotyktu (Deucravacitinib) has the potential to set a new benchmark as
FDA Approves Treatment for Patients with Moderate to Severe plaque psoriasis Disease Read More »
The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. After a long and winding drug development path for the common disease, Madrigal Pharmaceuticals’ resmetirom, to be sold under the brand name Rezdiffra, has become the first MASH
